[Moxetumomab pasudotox-Third line in Hairy cell leukemia]

Lydia Montes; Charles Herbaux

doi:10.1016/j.bulcan.2021.07.011

[Moxetumomab pasudotox-Third line in Hairy cell leukemia]

Bull Cancer. 2021 Dec;108(12):1073-1074. doi: 10.1016/j.bulcan.2021.07.011. Epub 2021 Nov 12.

[Article in French]

Authors

Lydia Montes¹, Charles Herbaux²

Affiliations

¹ CHU d'Amiens, service hématologie et thérapie cellulaire, 80000 Amiens, France. Electronic address: montes.lydia@chu-amiens.fr.
² CHU de Montpellier, service hématologie, 34295 Montpellier, France.

PMID: 34776118
DOI: 10.1016/j.bulcan.2021.07.011

No abstract available

Keywords: Anti-CD22 conjugated drug; Drogue conjuguée anti-CD22; Hairy cell leukemia; Leucémie à tricholeucocytes; Moxetumomab pasudotox; Rechute; Relapse.

Publication types

News

MeSH terms

Antineoplastic Agents / metabolism
Antineoplastic Agents / therapeutic use*
Bacterial Toxins / metabolism
Bacterial Toxins / therapeutic use*
Cladribine / therapeutic use
Exotoxins / metabolism
Exotoxins / therapeutic use*
Humans
Induction Chemotherapy / methods
Leukemia, Hairy Cell / complications
Leukemia, Hairy Cell / drug therapy*
Leukemia, Hairy Cell / metabolism
Pentostatin / therapeutic use
Recurrence
Retreatment / methods
Sialic Acid Binding Ig-like Lectin 2 / metabolism

Substances

Antineoplastic Agents
Bacterial Toxins
CD22 protein, human
Exotoxins
Sialic Acid Binding Ig-like Lectin 2
immunotoxin HA22
Pentostatin
Cladribine